(Press Release) Nippon Soda licenses MabGenesis’ therapeutic antibodies for feline inflammatory diseases

Nippon Soda Co., Ltd. announces that it has acquired a license from MabGenesis for the development and commercialization rights of therapeutic antibodies for feline inflammatory diseases developed by MabGenesis. Under this agreement, MabGenesis will receive an upfront payment and is entitled to receive milestone payments based on developmental progress as well as sales royalties.

Please see the joint press release here.